PPARA and metabolic dysfunction-associated steatotic liver disease: In patients with MASLD, particularly in the MASH stage, hepatic PPARα levels are significantly reduced and its activity is suppressed, leading to diminished fatty acid oxidation capacity and uncontrolled inflammation, thereby accelerating the progression from steatosis to hepatitis and fibrosis [44].